Metabolome analysis for pancreatic neuroendocrine tumor

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07193
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Kagawa University
• Principal Investigator: OKANO KEIICHI 香川大学, 医学部, 教授 (20314916)
• Co-Investigator(Kenkyū-buntansha): 曽我 朋義 慶應義塾大学, 環境情報学部(藤沢), 教授 (60338217)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 膵神経内分泌腫瘍 / キャピラリー電気泳動-質量分析(CE-MS) / メタボローム解析 / Creatine / SAH / N-Acetylgulutamate / 手術

Outline of Final Research Achievements

The pathogenesis of pancreatic neuroendocrine tumors (PanNEN) is highly diverse and unknown. We performed a metabolome analysis using CE-MS in PanNEN patients who underwent surgical treatment. Comparison of metabolites by WHO grade showed a significant increase in tumor creatine in G2 and G3. In the lymph node-positive group, five substances, N-Acetylgulutamate, SAH, Creatine, Glutatione, and UDP-glucuronate, were significantly increased in tumors. In particular, creatine was strongly associated with the grade of PanNEN, suggesting that creatine may be a potential therapeutic target and grading index in the future.

Free Research Field

腫瘍外科

Academic Significance and Societal Importance of the Research Achievements

手術治療を受けたPanNEN患者を対象として網羅的なタボローム解析をCE-MSを用いて行い、いくつかの重要な代謝経路と代謝産物を同定した。その中でリンパ節転移陽性群において優位に増加していたN-Acetylgulutamate, SAH, Creatine, Glutatione, UDP-glucuronateの5物質は今後の診断や治療に有用な候補代謝物である。特にCreatineはPanNENの悪性度とも強い関連を認め、Creatineが今後の新たな治療標的や悪性度評価指標となりうる可能性が示唆された。この成果はこれまで不明であったPanNENの代謝面での病態解明を大きく進めた。